Neurogeneration is a clinical stage biotechnology company developing repair strategies for aging and degenerative disorders of the central nervous system. Our proprietary products, derived from neural progenitor cells are expanded and characterized for therapies in advanced neurodegenerative disorde…
Neurogeneration is a clinical stage biotechnology company developing repair strategies for aging and degenerative disorders of the central nervous system. Our proprietary products, derived from neural progenitor cells are expanded and characterized for therapies in advanced neurodegenerative disorders like Parkinson’s disease. We believe our unique approach for restorative therapies, clinically safe following our proof of concept study, will be shown to be effective in a planned Phase II trial. Other pilot clinical trials are targeting underserved and under-penetrated markets with allogeneic clinical grade cell lines. Separately, our drug discovery division offers molecular profiling and disease modeling for cellular reprogramming and drug discovery platforms in partnerships with pharmaceutical companies
Team (1)
Sectors Neurogeneration serves:
Life Sciences
Health Care
Join Axial's Private M&A Platform
Neurogeneration connects with qualified M&A advisors through the Axial Platform.
Looking for Buyers?
Reach this investor and hundreds more on Axial. No cost to advisors.
